| Aug 8 |
Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others
|
| Aug 8 |
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
|
| Aug 8 |
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Recursion Pharmaceuticals GAAP EPS of -$0.40 misses by $0.02, revenue of $14.42M beats by $1.13M
|
| Aug 8 |
Nvidia-backed Recursion to acquire Exscientia in all-stock deal
|
| Aug 8 |
Recursion Pharmaceuticals: Q2 Earnings Snapshot
|
| Aug 8 |
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
|
| Aug 8 |
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
|
| Aug 8 |
Biotech firm Recursion to buy smaller peer Exscientia for $688 million
|
| Aug 8 |
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
|
